Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953118 · ClinicalTrials.gov registry record · Phase 4
Azithromycin for Meibomian Gland Disease
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03953118: Clinical Trial Phase 4 study, sponsored by University of California, San Francisco.
NCT03953118 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03953118, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.
Primary Outcome
Ocular surface disease index - used to evaluate the degree of dry eye symptoms. Scores will range from 0 to 48, where 48 indicates severe dry eye.
Interventions
- DRUG Placebo Oral
- DRUG Azithromycin Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 4 |
Why NCT03953118 stopped before completion
NCT03953118 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral is the first listed.
NCT03953118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03953118 about?
NCT03953118 is a clinical study titled "Azithromycin for Meibomian Gland Disease". This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.
What is the current status of trial NCT03953118?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2019-09-01. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03953118?
The interventions under investigation include: Placebo Oral (DRUG), Azithromycin Oral Product (DRUG).
Who is sponsoring clinical trial NCT03953118?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03953118's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI